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Objectives The aim of this study was to investigate the clinical characteristics and the long-term course of a large cohort of
patients with short QT syndrome (SQTS).
Background SQTS is a rare channelopathy characterized by an increased risk of sudden death. Data on the long-term out-
come of SQTS patients are not available.
Methods Fifty-three patients from the European Short QT Registry (75% males; median age: 26 years) were followed up
for 64  27 months.
Results A familial or personal history of cardiac arrest was present in 89%. Sudden death was the clinical presentation
in 32%. The average QTc was 314  23 ms. A mutation in genes related to SQTS was found in 23% of the pro-
bands; most of them had a gain of function mutation in HERG (SQTS1). Twenty-four patients received an im-
plantable cardioverter defibrillator, and 12 patients received long-term prophylaxis with hydroquinidine (HQ),
which was effective in preventing the induction of ventricular arrhythmias. Patients with a HERG mutation had
shorter QTc at baseline and a greater QTc prolongation after treatment with HQ. During follow-up, 2 already
symptomatic patients received appropriate implantable cardioverter defibrillator shocks and 1 had syncope.
Nonsustained polymorphic ventricular tachycardia was recorded in 3 patients. The event rate was 4.9% per year
in the patients without antiarrhythmic therapy. No arrhythmic events occurred in patients receiving HQ.
Conclusions SQTS carries a high risk of sudden death in all age groups. Symptomatic patients have a high risk of recurrent
arrhythmic events. HQ is effective in preventing ventricular tachyarrhythmia induction and arrhythmic events dur-
ing long-term follow-up. (J Am Coll Cardiol 2011;58:587–95) © 2011 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2011.03.038The association between long QT interval and sudden death
has been known for more than 50 years (1), but only recently
has interest moved to the opposite, a short QT interval. In
1993, Algra et al. (2) observed that both prolonged and
shortened corrected QT (QTc) intervals were associated
with an increased risk of sudden death (SD) compared with
intermediate QTc values. In 2000, Gussak et al. (3) reported
a family with short QT intervals (QTc 300 ms) and atrial
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011, accepted March 29, 2011.fibrillation (AF) in 1 of the members and an unrelated
woman with similar electrocardiography (ECG) changes
who died suddenly. Finally, our group in 2003 recognized
the short QT syndrome (SQTS) as a new clinical entity
related to familial SD with an autosomal dominant inheri-
tance (4), and the genetic nature of the disease was con-
firmed shortly after (5–8). Although the upper limit of
normal QT values is well defined, the lower limit has not
been determined to date. In the initial published cases of
SQTS, the QT and the QTc were constantly 300 ms or less.
In the subsequent years, individuals with SQTS and QTc
values of340 ms were reported in association with SD (9).
According to population studies, QTc of 360 ms or less or
QT of 88% or less of the predicted QT (QTp) have been
proposed as the lower limit of the normal QTc and QT,
because these correspond to the mean values minus 2
standard deviations in the general population (10).
The first proposed therapy was an implantable
cardioverter-defibrillator (ICD). Some studies have demon-
strated the efficacy of hydroquinidine (HQ) over a short-term
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Follow-Up of SQT Syndrome Patients August 2, 2011:587–95period and in a limited number of
patients (11,12). As SQTS has
been recognized only recently, data
regarding the long-term outcomes
of SQTS patients are not available.
The purposes of this study were,
first, to assess the clinical presen-
tation, the electrocardiographic
features, and the prevalence of
known genetic mutations and their
relationship with the long-term
prognosis in a large cohort of
SQTS patients and, second, to
verify the efficacy and the side
effects of the therapy, including
ICD and antiarrhythmic drugs.
Methods
Study population. From June
2002, SQTS patients from 7 European centers were en-
rolled in the European SQTS Registry. In the present study,
we included patients with a QTc of 360 ms or less (or88%
of QTp) associated with history of SD or aborted SD or
syncope of arrhythmic origin. Subjects with a very short QT
interval (QTc 340 ms) were included even if they were
asymptomatic. Family members of affected patients having a
short QT interval also were included in the study. The final
study group comprised 53 patients (75% males; median age:
26 years; interquartile range: 17 to 39 years) from 29
proband-identified families. Thirty-three patients already
have been reported in previous studies (4,9,11,13–15).
Four patients were included after SD, having ECG
documentation of short QT intervals before cardiac arrest.
There were 27 cases of SD without ECG documentation in
the families, which therefore were not included in the
present study.
Data collection and management. For each patient, data
on personal and family history, cardiac events, and therapy
were recorded. Between 1 and 8 (median: 2) 12-lead ECG
with a paper speed of 25 or 50 mm/s and a gain of 10
mm/mV were available and were analyzed for each patient.
The ECG parameters were measured with a 400% magni-
fication from the lead with the highest T-wave amplitude,
usually V2 or V3, by 3 independent examiners. Analyzed
ECG parameters were: heart rate, QRS interval duration,
QT interval, QTc, and QTp according to Rautaharju et al.’s
formula (16). Moreover, Jpoint–Tpeak, Q–Tpeak, Tpeak–
Tend, and Tpeak–Tend/QT ratio were evaluated. The QT
interval was measured manually according to the tangential
method; the Tpeak was measured from the highest point of
the T wave. Comparing the mean QT values obtained with
tangential (282 39) and threshold (291 42) methods by
paired t test, we found a statistically significant difference
(9.1  14; p  0.0001), however, with an excellent
Abbreviations
and Acronyms
AF  atrial fibrillation
CA  cardiac arrest
ECG  electrocardiography
EPS  electrophysiological
study
ERP  effective refractory
period
HQ  hydroquinidine
ICD  implantable
cardioverter-defibrillator
QTc  corrected QT
QTp  predicted QT
SD  sudden death
SQTS  short QT syndrome
VF  ventricular fibrillationagreement between the 2 methods (Pearson correlation wcoefficient [r]  0.94). It is already known that the first
method slightly underestimates the QT interval; however, it
has a similar or higher reproducibility (17); moreover, we
consider it particularly appropriate in SQT patients because
of the high-voltage T waves.
A baseline electrophysiological study (EPS) was per-
formed in 28 patients. In 8 patients, EPS was repeated
during oral HQ administration after the steady-state con-
centration was reached.
Altogether, 24 patients received an ICD and 12 patients
received long-term prophylaxis with HQ. One patient was
treated with amiodarone.
Follow-up. The follow-up time comprised historical clin-
ical information from birth to enrollment and the prospec-
tive follow-up information at 6-month intervals from en-
rollment through November 2010. Of the 53 patients, 4
died before clinical evaluation; 1 child died during the
follow-up at 4 months of age of noncardiac causes. The
parents of a child with ventricular fibrillation (VF) declined
to take part in the follow-up.
Statistical analysis. Comparisons between groups were
carried out with the chi-square test or Fisher exact test for
qualitative variables, and the 1-way analysis of variance
(ANOVA) or the t test for quantitative variables apart from
variables that have a skewed distribution and for which the
nonparametric Kruskal-Wallis or Mann–Whitney rank-
sum tests were used. We applied the Bonferroni correction
to address the problem of multiple comparisons. Parameters
before and after treatment were compared using the paired
t test or the Wilcoxon matched-pairs signed-rank tests. The
Kaplan–Meier product-limit estimator was used to compare
event incidence between different patient subgroups. The
log-rank or Wilcoxon tests were used to test the statistical
significance of the observed differences. To exclude that the
patients treated with HQ may be at higher or lower risk
based on other characteristics, we performed a comparison
of baseline clinical and demographic characteristics (gender,
age, previous events, and QTc at baseline) between the 2
groups. The multivariate logistic regression was performed
with Firth correction to avoid the problem of separation
resulting from having no event in HQ. All the tests were 2
tailed. A value of p  0.05 was considered statistically
significant.
Results
Demographic and clinical data. Thirty subjects (24 males
[80%]; median age: 23 years; interquartile range: 17 to 34
years) initially came to the observation for the following
reasons: SD (n 4), aborted SD (n 13), syncope (n 4),
ther symptoms (palpitations: n 3; effort dyspnea: n 1),
amily screening for SD (n  3), and ECG results recorded
or other reasons (n  2). Fifteen patients had a history of
amilial SD (50%).
After the screening of the related families, 23 subjects
ere added to the study population, 16 of whom were male,
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August 2, 2011:587–95 Follow-Up of SQT Syndrome Patientswith a median age of 32 years (interquartile range: 21 to 42
years). Considering the entire population, 33 of 53 patients
had symptoms at presentation (62%): 4 had died suddenly,
13 had an aborted SD (range: 3 months to 62 years), 8 had
syncope, 13 had palpitations (6 of whom had documented
AF or flutter). Frequent ventricular ectopic beats were
documented in 6 patients.
Two pediatric patients were affected by severe congenital
multiorgan disease; no cardiac involvement or acquired
causes that could determinate a short QT interval were
detected in any of these cases.
Cardiac arrest (CA) had a similar prevalence in males and
females (35% vs. 30%; p  0.15), and in both genders,
episodes at 1 year of age were reported. In males, more
than 90% of CA events occurred between 14 and 40 years of
age, whereas in females, the events were spread across the
Figure 1 Cardiac Events in Males and Females
Graph showing the age distribution of (A) sudden death and
(B) sudden death or syncope in males () and females ().
Comparison of Electrocardiographic Parameters Between PatientsWith P evious Cardiac A rest, Pat ents With Syncope, a d AsymptoTable 1 Comparison of Electro ardiographic Param ters BetweWith Previous Cardiac Arrest, Patients With Syncope,
All Patients (n  53) Cardiac Arrest (n  18)
HR (beats/min) 78 21 79 20
QRS (ms) 82 9 84 5
QT (ms) 282 39 278 44
QTc (ms) 314 23 311 25
QT/QTp (%) 76 6 75 6
J–Tpeak (ms) 121 29 113 35
Q–Tpeak (ms) 205 34 197 44
Tp–Te (ms) 77 16 78 14
Tp–Te/QT(%) 27 5 28 5Values are mean  SD.
HR  heart rate; J–Tpeak  Jpoint to T-wave peak; Q–Tpeak  Q to T-wave peak; QRS  QRS intervalentire lifespan; syncope was observed only in males and had
a similar age distribution (Fig. 1).
In the patients carrying a HERG mutation, a greater
proportion of affected females (55% vs. 18%; p  0.04) and
a higher prevalence of AF (36% vs. 3.6%; p  0.02) were
observed compared with non-HERG patients.
Genetic analysis. Genetic analysis was performed in 22 of
the index patients and revealed a mutation in 5. Four
families had a mutation in HERG, N588K in 2 (5) and
T618I in the other 2, a Chinese family (13) and a white
family (unpublished data from C. Antzelevitch group,
Masonic Medical Research Laboratory, Utica, New York):
both the mutations were in the pore loop of the HERG
channel. A family had a mutation in CACNB2b (8). The
test results were negative in 12 index patients, whereas in 5
cases, the analysis was still ongoing at the time of writing.
ECG. In all the available ECG, the average QT was 76 
% of the QTp (range: 59% to 86%); the average QT
nterval was 282  39 ms and the QTc was 314  23 ms
range: 250 to 350 ms).
No differences were found in the ECG parameters
etween symptomatic and asymptomatic patients (Table 1).
Brugada type 1 ECG and a shorter than normal QT
nterval were found in 3 patients: in 2 brothers with a
ACNB2b mutation and a history of CA in 1, the pattern
as observed after ajmaline challenge (8). The third case
as a 30-year-old man who sought treatment after a
octurnal syncope and showed a spontaneous type 1 ECG.
Comparing the ECG parameters between patients with a
utation in HERG with those without such a mutation,
T interval, QTc, QT/QTp, Jpoint–Tpeak, Tpeak–Tend,
nd Tpeak–Tend/QT ratio were significantly shorter in
ERG patients (Table 2).
lectrophysiological study. Twenty-eight patients under-
ent an EPS. The ventricular effective refractory periods
ERPs) at the right ventricular apex at a cycle length of 600
o 500 ms were shortened and varied between 140 and 200
s (mean: 166  21 ms). No differences were found
etween patients with a history of CA or syncope and those
ithout (right ventricular apex, S1S1 500 ms: 158  15 ms
s. 148  18 ms; p  0.21). VF was induced in 16 patients
c Patientsatients
symptomatic Patients
yncope (n  8) No Cardiac Arrest or Syncope (n  27) p Value
73 14 79 23 0.68
83 5 80 11 0.22
289 34 283 38 0.68
316 23 315 22 0.80
76 6 77 5 0.46
123 36 12623 0.51
210 35 208 28 0.76
80 13 75 19 0.79
28 6 26 5 0.44matien P
and A
S; QTc  corrected QT; QTp  predicted QT; Tp–Te  T-wave peak to T-wave end.
t
r
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Follow-Up of SQT Syndrome Patients August 2, 2011:587–95(57%): 3 had an aborted SD and 5 had syncope. Seven
(44%) of the 16 had mechanical induction of VF during
catheter positioning. In 12 patients, ventricular tachyar-
rhythmias were not induced: 5 had an aborted SD and 2 had
syncope. Because only 3 of the 8 patients with a history of
CA had inducible VF, EPS sensitivity was only 37%, and its
negative predictive value was 58%. The atrial ERPs also
were shortened and ranged between 120 and 200 ms (mean:
163  22 ms). AF was induced in 8 patients (36%).
Comparing the electrophysiological parameters between
patients with a mutation in HERG (n  7) and those
without (n  12), the ventricular ERPs were shorter in the
first group (151  14 ms vs. 176  24 ms; p  0.01).
Therapy. HYDROQUINIDINE. In 22 patients, HQ was tested
to assess its efficacy in prolonging the QT interval. In 6
cases, it was discontinued early because of poor therapeutic
compliance, in 2 cases because no effect on the QT was
observed, whereas 2 subjects (9%) reported gastroenteric
side effects. Twelve patients (8 adults and 4 children) had
been receiving HQ for a mean period of 76  30 months
(range: 27 to 105 months); the mean dosage in adults was
870  186 mg per day (range: 600 to 1,000 mg per day).
ECG before and after drug therapy were available for
analysis from 18 patients (Table 3). In 8 patients, the EPS
was repeated after the drug had reached the steady-state
concentration, in 6 cases via the ventricular lead of the ICD.
Ventricular ERPs were prolonged significantly (from 154
Comparison of Electrocardiographic ParametersBetween Patients With Mutation n HERGand Tho e W thout Mut tion in HERG
Table 2
Comparison of Electro ardiographic Parameters
Between Patients With Mutation in HERG
and Those Without Mutation in HERG
HERG (n  11) Non-HERG (n  28) p Value
HR (beats/min) 88 21 73 13 0.02
QRS (ms) 85 13 82 4 0.34
QT (ms) 253 26 292 32 0.0003
QTc 297 29 319 17 0.01
QT/QTp (%) 72 7 77 5 0.03
J–Tpeak (ms) 103 22 125 26 0.007
Q-Tpeak (ms) 187 35 208 27 0.05
Tp–Te (ms) 66 10 85 13 0.0002
Tp–Te/QT (%) 26 6 29 5 0.011
Values are mean  SD.
Abbreviations as in Table 1.
Comparison of Electrocardiographic ParametersBefore and After Initiation f Hydroquinidin in 1Table 3 Comparison of Electro ardiographicBefore and After Initiation of Hydro
All Patients (n  18) HER
QTc before HQ 307 20 29
QTc after HQ 384 39 40
Difference (p value) 10
QT/QTp before HQ 73 5 7
QT/QTp after HQ 91 9 9
Difference (p value) 2Values are mean  SE.
Abbreviations as in Table 1.12 ms to 205  23 ms; p  0.02). Seven patients had VF
induced at baseline (87%), whereas none had VF induced
after HQ (p  0.016). Comparing the ECG parameters in
patients with mutation in HERG with those without such
a mutation, the effect of HQ on QTc was more relevant and
constant in the first group, both in N588K and in T618I
carriers (Table 3, Fig. 2).
OTHER DRUGS. Experiences with drugs other than HQ are
reported in Table 4.
Amiodarone. Amiodarone was administered in 2 patients. It
did not produce any effect on the QT interval in a woman with
an HERG mutation. Another patient (male; QTc: 350 ms)
with documented VF at the age of 26 years and unknown
genotype (Figs. 3 and 4) received amiodarone and metoprolol:
he QTc was prolonged to 400 ms and no arrhythmias were
ecorded in a 6-month follow-up. Previous treatment with
tientsmeters
ine in 18 Patients
8) Non-HERG (n  10)
Difference Between
HERG and Non-HERG
(p Value)
3 313 17
0 362 36
4 49 9 56 16 (p 0.004)
75 4
86 7
11 2 14 4 (p 0.006)
Figure 2 Different Effect of Hydroquinidine in Patients With
HERG Mutation Versus Those Without HERG Mutation
Effect of hydroquinidine on the corrected QT (QTc) in patients (left) with a
HERG mutation compared with (right) those without a HERG mutation. Pre 
before treatment; post  during treatment.8 PaPar
quinid
G (n 
9 2
4 3
5 1
1 5
6 7
5 3
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August 2, 2011:587–95 Follow-Up of SQT Syndrome Patientssotalol was ineffective both in prolonging the QT interval and
in preventing ventricular tachyarrhythmias.
Disopyramide. Three patients with inducible VF at base-
line, 1 who was asymptomatic with unknown genotype and
2 with paroxysmal AF and HERG mutation, underwent an
antiarrhythmic drug trial with oral disopyramide (200 to
400 mg per day). VF was still inducible in the patient taking
the lower dosage, and no changes were observed in the
ventricular ERPs. In the patients taking the higher dosage,
the QTc prolonged slightly (Table 4), and the ventricular
ERP prolonged from 160 to 200 ms in 1 case; these latter
data have been reported already (18).
Follow-up. Forty-seven patients were followed up over
64  27 months (Fig. 5).
PATIENTS WITH A PREVIOUS CARDIAC ARREST. Twelve pa-
tients had an aborted SD. An ICD was implanted in 11
patients. One child with an HERG mutation (4) had CA at
the age of 8 months, with severe neurologic damage. He did
not undergo ICD implantation and received HQ from the
age of 6 years, which effectively prolonged the QT interval.
Two patients started HQ at the time of ICD implantation,
which was discontinued after a few days in 1 patient (9).
During follow-up, 1 patient repeatedly received appro-
priate shocks on VF and was treated with amiodarone with
success. One patient received inappropriate ICD shocks
because of atrial flutter; he underwent successful cavotricus-
pid isthmus ablation and was started on oral HQ. One
patient had 2 asymptomatic episodes of polymorphic non-
sustained ventricular tachycardia.
PATIENTS WITH A HISTORY OF SYNCOPE. Eight patients
had syncope at presentation: 4 received an ICD, 3 declined
Patients With Available Data to Compare the Efficacy of HydroquinTable 4 Patients With Available Data to Compare the Efficacy
Patient Age, Gender, HERG Status Drug Dosage
31 yrs, female, HERG Basal ECG
Amiodarone 200 mg
Sotalol 80 mg twice d
Hydroquinidine 250 mg thrice
35 yrs, male, HERG Basal ECG
Sotalol 80 mg twice d
Hydroquinidine 250 mg thrice
71 yrs, female, HERG Basal ECG
Disopyramide 400 mg/day
Hydroquinidine 500 mg twice
44 yrs, female, HERG Basal ECG
Disopyramide 400 mg/day
Hydroquinidine 500 mg twice
43 yrs, male, non-HERG Basal ECG
Disopyramide 100 mg twice
Hydroquinidine 300 mg twice
29 yrs, male, non-HERG Basal ECG
Sotalol 80 mg thrice d
Amiodarone 200 mg twice
ECG  electrocardiography; other abbreviations as in Table 1.the ICD, and in 1 case, the patient was judged to be at lowrisk (a 23-year-old man with no familial history of SD and
probably vasovagal syncope). Of the 3 patients who declined
the implant, one was a 70-year-old man with permanent AF
and familial history of SD who declined any treatment; the
others were 2 brothers with a family history of SD with an
unknown genotype and inducible VF during EPS, who
received HQ (9).
The only event during the follow-up occurred in a patient
with a HERG mutation (SQTS1) who received an appro-
priate shock on VF 11 months after the implantation. He
was a 16-year-old male with syncope at the age of 8 months
and a family history of SD over 3 generations (4,14).
PATIENTS ASYMPTOMATIC FORCARDIACARRESTOR SYNCOPE.
Twenty-seven patients were asymptomatic for CA and
syncope. Eight of them had AF or palpitations. An ICD
was implanted in 9 patients because of a family history of
SD, induction of VF at EPS, or both (9,13). Seven patients
also received HQ, but it was soon interrupted in 5 patients.
Oral HQ alone was started in 2 adult patients with family
history of SD who stopped it early and in a 25-year-old
patient with permanent AF (15). Moreover, HQ therapy
was started in 3 children (2 younger than 1 year), and the
drug was well tolerated (9).
During follow-up, 1 patient experienced a syncope, and 2
other patients had episodes of nonsustained ventricular
tachycardia documented by the ICD: none of them were
receiving pharmacological prophylaxis (9).
The event rate in the whole population was 3.3% per year.
All the events occurred in patients who were not receiving
HQ: in this group, the event rate was 4.9% per year, whereas
no arrhythmic events occurred in those receiving HQ (Fig. 6).
With Other Antiarrhythmic Treatmentsdroquinidine With Other Antiarrhythmic Treatments
HR (beats/min) QT (ms) QTc (ms) QT/QTp (%)
86 250 300 71
71 260 284 68
63 280 287 70
85 360 428 102
66 270 283 68
63 260 266 65
60 380 380 93
77 291 329 79
86 299 358 85
75 342 382 91
70 292 315 76
79 290 333 79
81 318 370 88
290 338 80
95 290 365 86
97 270 343 81
81 300 349 83
54 350 332 82
60 400 400 98idineof Hy
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Follow-Up of SQT Syndrome Patients August 2, 2011:587–95significantly different between the 2 groups, with a shorter
mean QTc before therapy in the group receiving HQ.
ICD-RELATED COMPLICATIONS. Fourteen patients (58%)
f 24 had complications related to the ICD. In 8 subjects,
nappropriate shocks were observed: 4 patients with a
ERG mutation received inappropriate shocks shortly after
mplantation (within 2 months) because of T-wave over-
ensing (19). No recurrences were reported after the new
rogramming of the ICD. The other 4 patients had inap-
ropriate shocks during episodes of supraventricular tachy-
ardia. Three patients had ICD lead replacement because of
ead fracture, and a fourth patient had ICD lead replace-
ent because of an infection of the ICD system; 1 patient
ad early substitution of the ICD because of a recall. One
Figure 3 Nonsustained Ventricular Tachycardia
Polymorphic nonsustained ventricular tachycardia recorded in a patient with histor
implantable cardioverter-defibrillator (Holter monitoring; paper speed, 25 mm/s).ad severe psychological distress. biscussion
n the present study, the long-term outcome of 53 patients
ith SQTS is reported, representing the largest series in the
iterature. Clinical characteristics, therapy efficacy, and the
utcome after the diagnosis were analyzed. The follow-up
as almost complete, with only 1 patient not participating.
lmost 90% of the patients had a personal or familial
istory of SD at presentation. A prevalence of males was
bserved, and the mean age was between 20 and 30 years.
ore than 60% of the subjects had symptoms at presenta-
ion: the most frequent symptom was CA, which repre-
ented the first clinical manifestation in one third of the
atients. It was observed also in infants in their first months
f life. Most of the events occurred in males, mainly
dden death and repeated shocks of they of suetween the second and the fourth decade. This distribution
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August 2, 2011:587–95 Follow-Up of SQT Syndrome Patientsof events corresponds to the age with the highest testoster-
one plasma levels (20). Androgens, and specifically testos-
terone, cause a shortening of the QT in boys after puberty,
which is responsible for the fact that women exhibit QTc
Figure 4 Ventricular Fibrillation Recorded by the Implantable C
Same patient as in Figure 3. The arrhythmia is triggered by a short-coupled ventric
Figure 5 Therapeutic Approach
Schematic representation of therapeutic approach and follow-up of the entire popu
NSVT  nonsustained ventricular tachycardia; pts  patients; VF  ventricular fibintervals significantly longer than men (21). These hormonal
influences may provide relative protection to post-puberal boys
and men in the context of the long QT syndrome (22).
However, the possible relationship of testosterone with suscep-
verter-Defibrillator
xtrasystole.
. Hq  hydroquinidine; ICD  implantable cardioverter-defibrillator;
.ardio
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Follow-Up of SQT Syndrome Patients August 2, 2011:587–95tibility for cardiac arrhythmias in the context of SQTS needs to
be investigated further. Syncope was the second most frequent
clinical manifestation, in 15% of cases. The finding of several
episodes of nonsustained ventricular tachycardia recorded by
the ICD or during telemetry in our patients seems to confirm
that self-terminating episodes of VT or VF may be the cause of
syncope in SQTS (Figs. 3 and 4). CA and syncope occurred
oth at rest and during effort, so that it was not possible to
dentify a uniform trigger for the events. AF or atrial flutter
ere observed in 15% of the population, also younger than 35
ears.
Concerning the ECG parameters, we considered a con-
istently short QT interval (QTc 340 ms) among the
nclusion criteria in the study (9), even in the absence of
ymptoms or family history of SD. Moreover, we decided to
Figure 6 Different Incidence of Arrhythmic Events in Patients T
Kaplan-Meier estimate of survival free of major arrhythmic events during a 5-year f
hydroquinidine (Hq) with those without therapy. The difference is not statistically s
Comparison of Baseline Clinical and Demographicharacteristics Betwe n Patients Rec ivingHyd oquin dine and Those Not Receiving
Table 5
Comparison of Baseline Clinical and Demographic
Characteristics Between Patients Receiving
Hydroquinidine and Those Not Receiving
Hydroquinidine
HQ (n  12) No HQ (n  35) p Value
Male (%) 9 (75%) 28 (80%) 0.70*
Age at first visit 27 21 32 18 0.41†
Symptomatic for CA
or syncope (%)
6 (50%) 14 (40%) 0.74*
CA (%) 3 (25%) 9 (26%) 0.99*
Syncope (%) 3 (25%) 5 (14%) 0.40*
Asymptomatic (%) 6 (50%) 21 (60%) 0.74*
QTc at baseline 302 23 320 20 0.01†r
Values are n (%) or mean  SD. *Fisher exact test. †t test.
CA  cardiac arrest; HQ  hydroquinidine; other abbreviations as in Table 1.nclude also patients with a QTc of 360 ms or less and a
istory of SD or aborted SD or syncope of arrhythmic
rigin. In this larger population, the previous observation
9) that the QTc values in a population with short QT did
ot distinguish between asymptomatic subjects and those
ith CA was confirmed. In a recent paper by Anttonen et
l. (23), it was shown that parameters such as the Jpoint–
peak interval and Tpeak–Tend/QTc may differentiate
atients with SQTS and CA from asymptomatic subjects
ith a shorter than normal QT interval from the general
opulation. None of these indexes, however, could discrim-
nate, in our population of patients with SQTS, asymptom-
tic SQT subjects from those with CA or syncope (Table 1).
urthermore, EPS was not useful in predicting CA, having
sensitivity of only 37%.
The yield of genetic screening in SQTS was 23% of the
nvestigated index patients. Mutations predominantly
ere found in KCNH2/HERG (4 of the 5 with a positive
enotype), whereas a loss of function mutation in the
ACNB2b gene was found in another family. Patients
ith a HERG mutation constituted a subgroup with
pecific characteristics such as a greater proportion of
ffected females and a higher prevalence of AF compared
ith non-HERG patients. Moreover, they exhibited
horter QT intervals and ERPs.
HQ was tested in 41% of the patients. In the patients
ith a HERG mutation, HQ induced normalization of the
T interval and of the ERPs, whereas in those without the
utation, a weaker effect and a significant variability of
d With Hydroquinidine and Without Therapy
p in a comparison of patients treated with
nt.reate
ollow-u
ignificaesponses were observed. HQ prevented the induction of
p
I
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August 2, 2011:587–95 Follow-Up of SQT Syndrome Patientsventricular arrhythmias during EPS in all studied patients,
and none of the treated patients had arrhythmic events
during the follow-up. Drug tolerability was good: Only 9%
of the patients interrupted it because of side effects (gastro-
enteric intolerance or dermatitis). HQ was used in adults
mainly as a prophylaxis for AF or flutter, but also in patients
who had declined an ICD implant and in children both as
primary and secondary prevention after VF. HQ served as a
valuable bridge to ICD. However, unfortunately quinidine
became no longer available in several European countries for
commercial reasons (24).
The incidence of arrhythmic events during the follow-up
was 4.9% per year in the patients without pharmacological
prophylaxis, whereas no arrhythmic events occurred in those
receiving HQ. VF occurred in already symptomatic pa-
tients. No events were recorded among treated patients,
even if previously symptomatic. For this reason, HQ may be
considered as an alternative option to ICD in patients who
cannot receive it (children) or who decline the implant, but
it is still underused. Fifty-eight percent of the patients with
an ICD had complications related to the device. Many were
inappropriate shocks, secondary to T-wave oversensing with
double counting of the R and T waves, which occurred early
after the implant (19) and were prevented with correct
ventricular sensitivity programming for VF detection.
Future perspectives. The current study included only
asymptomatic patients if they had very short QT intervals.
In the future, it would be important to expand this registry,
including also asymptomatic subjects with borderline short
QT intervals, to understand better the prognosis and to help
guide the management of such patients.
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